Free Newsletter
Lilly cited for"misleading" Cymbalta ads
Free newsletter via e-mail
Tools
While Eli Lilly's CEO was out lobbying for drug safety, the FDA was posting a letter on its website warning the drug maker to stop making "false and misleading" claims about its antidepressant Cymbalta.
At issue was a promotional mailing that left out some of the drug's most serious side effects and exaggerated its effectiveness at easing pain. (In addition to its approval for use in depression and anxiety, Cymbalta is approved for diabetic nerve pain.) The agency ordered Lilly to stop distributing the mailer--which was first used in 2005.
- check out the warning letter from the FDA
Related Article:
Lilly pursues new Cymbalta approval. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
